News
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...
Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...
The Score is a weekly review of the biggest stock moves and the news that drove them. Here is this week's installment: ...
And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...
Pfizer (PFE) recently announced that the U.S. Food and Drug Administration accepted the New Drug Application for ...
Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results